These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 12057670)

  • 1. X-ray crystallographic structure of ABT-378 (lopinavir) bound to HIV-1 protease.
    Stoll V; Qin W; Stewart KD; Jakob C; Park C; Walter K; Simmer RL; Helfrich R; Bussiere D; Kao J; Kempf D; Sham HL; Norbeck DW
    Bioorg Med Chem; 2002 Aug; 10(8):2803-6. PubMed ID: 12057670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interactions of different inhibitors with active-site aspartyl residues of HIV-1 protease and possible relevance to pepsin.
    Sayer JM; Louis JM
    Proteins; 2009 May; 75(3):556-68. PubMed ID: 18951411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease.
    Sham HL; Kempf DJ; Molla A; Marsh KC; Kumar GN; Chen CM; Kati W; Stewart K; Lal R; Hsu A; Betebenner D; Korneyeva M; Vasavanonda S; McDonald E; Saldivar A; Wideburg N; Chen X; Niu P; Park C; Jayanti V; Grabowski B; Granneman GR; Sun E; Japour AJ; Leonard JM; Plattner JJ; Norbeck DW
    Antimicrob Agents Chemother; 1998 Dec; 42(12):3218-24. PubMed ID: 9835517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crystal structures of a multidrug-resistant human immunodeficiency virus type 1 protease reveal an expanded active-site cavity.
    Logsdon BC; Vickrey JF; Martin P; Proteasa G; Koepke JI; Terlecky SR; Wawrzak Z; Winters MA; Merigan TC; Kovari LC
    J Virol; 2004 Mar; 78(6):3123-32. PubMed ID: 14990731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enzymatic and structural analysis of the I47A mutation contributing to the reduced susceptibility to HIV protease inhibitor lopinavir.
    Sasková KG; Kozísek M; Lepsík M; Brynda J; Rezácová P; Václavíková J; Kagan RM; Machala L; Konvalinka J
    Protein Sci; 2008 Sep; 17(9):1555-64. PubMed ID: 18560011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural analysis of an HIV-1 protease I47A mutant resistant to the protease inhibitor lopinavir.
    Kagan RM; Shenderovich MD; Heseltine PN; Ramnarayan K
    Protein Sci; 2005 Jul; 14(7):1870-8. PubMed ID: 15937277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crystallographic study of multi-drug resistant HIV-1 protease lopinavir complex: mechanism of drug recognition and resistance.
    Liu Z; Yedidi RS; Wang Y; Dewdney TG; Reiter SJ; Brunzelle JS; Kovari IA; Kovari LC
    Biochem Biophys Res Commun; 2013 Jul; 437(2):199-204. PubMed ID: 23792096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insights into the mechanism of drug resistance: X-ray structure analysis of multi-drug resistant HIV-1 protease ritonavir complex.
    Liu Z; Yedidi RS; Wang Y; Dewdney TG; Reiter SJ; Brunzelle JS; Kovari IA; Kovari LC
    Biochem Biophys Res Commun; 2013 Feb; 431(2):232-8. PubMed ID: 23313846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oximinoarylsulfonamides as potent HIV protease inhibitors.
    Yeung CM; Klein LL; Flentge CA; Randolph JT; Zhao C; Sun M; Dekhtyar T; Stoll VS; Kempf DJ
    Bioorg Med Chem Lett; 2005 May; 15(9):2275-8. PubMed ID: 15837308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and structure-activity relationships of a novel series of HIV-1 protease inhibitors encompassing ABT-378 (Lopinavir).
    Sham HL; Betebenner DA; Chen X; Saldivar A; Vasavanonda S; Kempf DJ; Plattner JJ; Norbeck DW
    Bioorg Med Chem Lett; 2002 Apr; 12(8):1185-7. PubMed ID: 11934584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 protease mutations and inhibitor modifications monitored on a series of complexes. Structural basis for the effect of the A71V mutation on the active site.
    Skalova T; Dohnalek J; Duskova J; Petrokova H; Hradílek M; Soucek M; Konvalinka J; Hasek J
    J Med Chem; 2006 Sep; 49(19):5777-84. PubMed ID: 16970402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing the accumulation of active- and nonactive-site mutations in the HIV-1 protease.
    Clemente JC; Moose RE; Hemrajani R; Whitford LR; Govindasamy L; Reutzel R; McKenna R; Agbandje-McKenna M; Goodenow MM; Dunn BM
    Biochemistry; 2004 Sep; 43(38):12141-51. PubMed ID: 15379553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolism and disposition of the HIV-1 protease inhibitor lopinavir (ABT-378) given in combination with ritonavir in rats, dogs, and humans.
    Kumar GN; Jayanti VK; Johnson MK; Uchic J; Thomas S; Lee RD; Grabowski BA; Sham HL; Kempf DJ; Denissen JF; Marsh KC; Sun E; Roberts SA
    Pharm Res; 2004 Sep; 21(9):1622-30. PubMed ID: 15497688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unexpected binding mode of a cyclic sulfamide HIV-1 protease inhibitor.
    Bäckbro K; Löwgren S; Osterlund K; Atepo J; Unge T; Hultén J; Bonham NM; Schaal W; Karlén A; Hallberg A
    J Med Chem; 1997 Mar; 40(6):898-902. PubMed ID: 9083478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. P1 and P1' para-fluoro phenyl groups show enhanced binding and favorable predicted pharmacological properties: structure-based virtual screening of extended lopinavir analogs against multi-drug resistant HIV-1 protease.
    Yedidi RS; Liu Z; Kovari IA; Woster PM; Kovari LC
    J Mol Graph Model; 2014 Feb; 47():18-24. PubMed ID: 24291501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and synthesis of HIV-1 protease inhibitors incorporating oxazolidinones as P2/P2' ligands in pseudosymmetric dipeptide isosteres.
    Reddy GS; Ali A; Nalam MN; Anjum SG; Cao H; Nathans RS; Schiffer CA; Rana TM
    J Med Chem; 2007 Sep; 50(18):4316-28. PubMed ID: 17696512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. X-ray structure of HIV-1 protease tethered dimer complexed to ritonavir.
    Das A; Rao DR; Hosur MV
    Protein Pept Lett; 2007; 14(6):565-8. PubMed ID: 17627597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Computational studies of the resistance patterns of mutant HIV-1 aspartic proteases towards ABT-538 (ritonavir) and design of new derivatives.
    Nair AC; Bonin I; Tossi A; Wels WJ; Miertus S
    J Mol Graph Model; 2002 Dec; 21(3):171-9. PubMed ID: 12463635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A distinct binding mode of a hydroxyethylamine isostere inhibitor of HIV-1 protease.
    Dohnálek J; Hasek J; Dusková J; Petroková H; Hradilek M; Soucek M; Konvalinka J; Brynda J; Sedlácek J; Fábry M
    Acta Crystallogr D Biol Crystallogr; 2001 Mar; 57(Pt 3):472-6. PubMed ID: 11223536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A structural and thermodynamic escape mechanism from a drug resistant mutation of the HIV-1 protease.
    Vega S; Kang LW; Velazquez-Campoy A; Kiso Y; Amzel LM; Freire E
    Proteins; 2004 May; 55(3):594-602. PubMed ID: 15103623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.